1. Structure and inhibition of Cryptococcus neoformans sterylglucosidase to develop antifungal agents.
- Author
-
Pereira de Sa N, Taouil A, Kim J, Clement T, Hoffmann RM, Burke JE, Rizzo RC, Ojima I, Del Poeta M, and Airola MV
- Subjects
- Animals, CD4-Positive T-Lymphocytes, Catalytic Domain, Cryptococcosis, Cryptococcus neoformans genetics, Crystallography, X-Ray, Disease Models, Animal, Drug Discovery, Ergosterol, Female, Fungal Proteins genetics, Glucosidases chemistry, Glucosidases drug effects, Glucosidases genetics, High-Throughput Screening Assays, Mice, Models, Molecular, Molecular Docking Simulation, Antifungal Agents chemistry, Antifungal Agents pharmacology, Cryptococcus neoformans drug effects, Fungal Proteins chemistry, Fungal Proteins drug effects
- Abstract
Pathogenic fungi exhibit a heavy burden on medical care and new therapies are needed. Here, we develop the fungal specific enzyme sterylglucosidase 1 (Sgl1) as a therapeutic target. Sgl1 converts the immunomodulatory glycolipid ergosterol 3β-D-glucoside to ergosterol and glucose. Previously, we found that genetic deletion of Sgl1 in the pathogenic fungus Cryptococcus neoformans (Cn) results in ergosterol 3β-D-glucoside accumulation, renders Cn non-pathogenic, and immunizes mice against secondary infections by wild-type Cn, even in condition of CD4+ T cell deficiency. Here, we disclose two distinct chemical classes that inhibit Sgl1 function in vitro and in Cn cells. Pharmacological inhibition of Sgl1 phenocopies a growth defect of the Cn Δsgl1 mutant and prevents dissemination of wild-type Cn to the brain in a mouse model of infection. Crystal structures of Sgl1 alone and with inhibitors explain Sgl1's substrate specificity and enable the rational design of antifungal agents targeting Sgl1., (© 2021. The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF